Aflibercept shows reduction in macular and choroidal thickness in patients with AMD

Substantial improvements in visual acuity and notable reductions in both macular and choroidal thickness were seen among patients with neovascular age-related macular degeneration (AMD) who underwent intravitreal aflibercept injections, according to a study.

After receiving treatment with aflibercept, there was a significant improvement in the best-corrected mean visual acuity. The visual acuity, initially measured at 1.0 logarithm of the minimum resolution angle (logMAR) units, decreased to 0.55 logMAR after the treatment. Patients undergoing treatment exhibited a significant decrease in average macular thickness from 323 μm to 232 μm (P = 0.001), as well as a reduction in choroidal thickness from 206 μm to 172 μm (P = 0.031).

Statistically significant associations were found between the difference in pre- and post-treatment choroidal thickness and pretreatment values of macular thickness (P = 0.005) and choroidal thickness (P = 0.013).

Reference
Beraldo DP, Rezende MP, Alexander JG, et al. Correlations between subfoveal choroidal thickness, macular thickness, and visual outcome in neovascular age-related macular degeneration using swept source OCT: insights from intravitreal aflibercept treatment. Int J Retina Vitreous. 2023;9(1):70. doi: 10.1186/s40942-023-00506-4. PMID: 37968771.